Our theme for 2020 was Hope. 2020 presented a challenge to us all, but most especially to our patients and caregivers who are seeking to survive this rare cancer. In 2020, The Life Raft Group needed to provide a lifeline to our community, and to offer them hope in the form of increased support as we navigate the challenges of living in a COVID-19 world. #GISTHope
The LRG will be collaborating with the NIH again in 2021 to hold the Virtual GIST Tumor Board in place of the NIH's Pediatric & Wildtype GIST Clinic normally held in the DC area. Applications to have cases reviewed are now open.
It's time to fully unleash the power of biomarker testing to support precision oncology - all GIST patients should have biomarker (mutational) testing for the best possible personalized treatment plan.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video shows the action steps of our It's Time campaign.
This video contains information about Gastrointestinal Stromal Tumor (GIST) presented by Dr. Sameer Rastogi, All India Institute of Medical Sciences, New Delhi, India.
This video deals with the mechanism of avapritinib in GIST, current outcomes and challenges with PDGFRA D842V mutated GIST presented by Dr. Sameer Rastogi, All India Institute of Medical Sciences, New Delhi, India..
The Life Raft Group is pleased to present the members of the LRG 2021 Medical Advisory Board. Members will play a crucial role in offering expert opinions on research and medical developments.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important and about terminology when talking about mutations.
The National Organization for Rare Disorders (NORD) held a webinar on February 19th, 2021 for NORD member organizations as well as leaders and staff of nonprofits organizations involved in rare diseases including pharma, patients, caregivers, and advocates.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
